| Literature DB >> 31308453 |
Jiajia Yang1,2, Xingxing Hu1,2, Meng Wu1,2, Yubo Ma1,2, Xu Zhang1,2, Mengya Chen1,2, Yaping Yuan1,2, Renfang Han1,2, Rui Liu1,2, Shiyang Guan1,2, Jixiang Deng1,2, Shanshan Xu1,2, Xing Gao1,2, Shengqian Xu3, Zongwen Shuai3, Shanqun Jiang4, Shihe Guan5, Liwen Chen5, Faming Pan6,7.
Abstract
This study was conducted to clarify the associations of tumor necrosis factor-α induced protein 3 (TNFAIP3) and TNFAIP3-interacting protein 1 (TNIP1) genetic polymorphisms with ankylosing spondylitis (AS) susceptibility. Five single nucleotide polymorphisms (SNPs) in TNFAIP3 gene and four in TNIP1 gene were genotyped in 667 AS patients and 667 matched healthy controls. Genotypes and haplotype analysis were conducted by using SPSS 23.0 and Haploview 4.2 software. The T allele and CT genotype in TNFAIP3 rs10499194 were significantly associated with a reduced AS risk (T allele vs. C allele, OR = 0.619, 95% CI = 0.430-0.889, P = 0.009; CT vs. CC, OR = 0.603, 95% CI = 0.416-0.875, P = 0.007). However, no association remained significant after Bonferroni correction. The rs13207033A- rs10499194T haplotype of TNFAIP3 conferred a protective effect on AS susceptibility. Stratification analyses suggested that rs10499194 polymorphism decreased the risk of AS in the male subgroup, subgroup aged ≥ 29, HLA-B27 positive subgroup as well as the subgroups of BASFI < 4 and BASDAI < 4 (all P < 0.05). Furthermore, the functional annotation suggested a potential function of rs10499194 mutation. Our results demonstrated that TNFAIP3 rs10499194 polymorphism may be associated with a reduced risk of AS.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31308453 PMCID: PMC6629655 DOI: 10.1038/s41598-019-46647-1
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Demographic and clinical characteristics of participants.
| AS (n = 667) | HC (n = 667) |
| |
|---|---|---|---|
| Gender (male/female) | 542/125 | 559/108 | 0.220 |
| Age (years, mean ± SD) | 28.47 ± 9.08 | 28.88 ± 7.68 | 0.369 |
| BMI (kg/m 2, mean ± SD) | 22.23 ± 3.97 | ||
| Age at presentation(years, mean ± SD) | 23.60 ± 9.77 | ||
| Disease course (year, median (IQR)) | 3.00 (1.00, 8.00) | ||
| HLA-B27 positivity (%) | 412 (61.78%) | ||
| ESR (mm/h, median(IQR)) | 15.00 (5.00, 33.00) | ||
| CRP (mg/L, median (IQR)) | 9.89 (2.64, 29.92) | ||
| WBC (/L, median (IQR)) | 7.08 (5.86, 8.40) | ||
| BASDAI (score, median (IQR)) | 2.00 (0.60, 3.80) | ||
| BASFI (score, median (IQR)) | 0.90 (0.00, 2.60) |
AS, ankylosing spondylitis; HC, healthy controls; BMI, body mass index; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; WBC, white blood cell; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index.
The allele and genotype frequencies of TNFAIP3 and TNIP1 genes polymorphisms
| SNPs | Genotype | Allele |
| |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AS (n, %) | HC (n, %) |
|
| AS (n, %) | HC (n, %) | OR (95% CI) |
|
| ||||
|
| ||||||||||||
| rs610604 | TT | 553 (82.9) | 553 (82.9) | 0.859 | NS | T | 1214 (91.0) | 1212 (90.9) | (Reference) | 0.259 | ||
| GT | 108 (16.2) | 106 (15.9) | G | 120 (9.0) | 122 (9.1) | 0.982 (0.754–1.279) | 0.893 | NS | ||||
| GG | 6 (0.9) | 8 (1.2) | ||||||||||
| rs10499194 | CC | 617 (92.5) | 588 (88.2) | 0.007a | NS | C | 1284 (96.3) | 1255 (94.1) | (Reference) | 0.104 | ||
| CT | 50 (7.5) | 79 (11.8) | T | 50 (37.5) | 79 (5.9) | 0.619 (0.430–0.889) | 0.009a | NS | ||||
| TT | 0 | 0 | ||||||||||
| rs13207033 | GG | 544 (81.6) | 517 (77.5) | 0.181 | NS | G | 1201 (90.0) | 1173 (87.9) | (Reference) | 0.639 | ||
| GA | 113 (16.9) | 139 (20.8) | A | 133 (10.0) | 161 (12.1) | 0.807 (0.633–1.029) | 0.083 | NS | ||||
| AA | 10 (1.5) | 11 (1.7) | ||||||||||
| rs2230926 | TT | 621 (93.1) | 614 (92.1) | 0.317 | NS | T | 1288 (96.6) | 1279 (95.9) | (Reference) | 0.396 | ||
| GT | 46 (6.9) | 51 (7.6) | G | 46 (3.4) | 55 (4.1) | 0.831 (0.557–1.238) | 0.361 | NS | ||||
| GG | 0 | 2 (0.3) | ||||||||||
| rs6920220 | GG | 660 (99.0) | 662 (99.3) | 0.562 | NS | G | 1327 (99.5) | 1329 (99.6) | (Reference) | 0.923 | ||
| GA | 7 (1.0) | 5 (0.7) | A | 7 (0.5) | 5 (0.4) | 1.402 (0.444–4.429) | 0.563 | NS | ||||
| AA | 0 | 0 | ||||||||||
| TNIP1 | ||||||||||||
| rs2233287 | GG | 662 (99.3) | 667 (100) | 0.073 | NS | G | 1329 (99.6) | 1334 (100) | (Reference) | 1.000 | ||
| GA | 5 (0.7) | 0 | A | 5 (0.4) | 0 | 0.996 (0.993–1.000) | 0.073 | NS | ||||
| AA | 0 | 0 | ||||||||||
| rs4958881 | TT | 563 (84.4) | 560 (84.0) | 0.829 | NS | T | 1225 (91.8) | 1220 (91.5) | (Reference) | 0.292 | ||
| CT | 99 (14.8) | 100 (15.0) | C | 109 (8.2) | 114 (8.5) | 0.952 (0.724–1.253) | 0.727 | NS | ||||
| CC | 5 (0.8) | 7 (1.0) | ||||||||||
| rs3792783 | AA | 392 (58.8) | 398 (59.7) | 0.635 | NS | A | 1030 (77.2) | 1030 (77.2) | (Reference) | 0.937 | ||
| GA | 246 (36.9) | 234 (35.1) | G | 304 (22.8) | 304 (22.8) | 1.000 (0.835–1.198) | 1.000 | NS | ||||
| GG | 29 (4.3) | 35 (5.2) | ||||||||||
| rs6889239 | CC | 382 (57.3) | 375 (56.2) | 0.902 | NS | C | 1006 (75.4) | 1000 (75.0) | (Reference) | 0.969 | ||
| CT | 242 (36.3) | 250 (37.5) | T | 328 (24.6) | 334 (25.0) | 0.976 (0.819–1.164) | 0.788 | NS | ||||
| TT | 43 (6.4) | 42 (6.3) | ||||||||||
AS, ankylosing spondylitis; HC, healthy controls; SNPs, single nucleotide polymorphisms; OR, odds ratio; CI, confidence interval; HWE, Hardy-Weinberg equilibrium test; TNFAIP3, tumor necrosis factor-α induced protein 3; TNIP1, TNFAIP3-interacting protein 1; NS, not significant; Pc, Bonferroni corrected P-value; aP < 0.05 after adjusting sex and age.
Stratification analyses by sex, age, HLA-B27 status, BASFI and BASDAI for rs10499194 polymorphism.
| Stratum | OR(95% CI) |
| Adjusted ORa (95% CI) |
|
|---|---|---|---|---|
|
| ||||
| Male | 0.627 (0.421–0.934) | 0.021 | 0.620 (0.416–0.924) | 0.019 |
| Female | 0.494 (0.173–1.408) | 0.180 | 0.498 (0.175–1.421) | 0.193 |
|
| ||||
| <29 | 0.666 (0.414–1.071) | 0.092 | 0.659 (0.406–1.069) | 0.091 |
| ≥29 | 0.517 (0.284–0.941) | 0.029 | 0.533 (0.292–0.974) | 0.041 |
|
| ||||
| HLA-B27(+) | 0.543 (0.346–0.851) | 0.007 | 0.547 (0.349–0.859) | 0.009 |
| HLA-B27(−) | 0.703 (0.428–1.154) | 0.162 | 0.694 (0.422–1.142) | 0.150 |
|
| ||||
| <4 | 0.590 (0.394–0.886) | 0.010 | 0.587 (0.391–0.881) | 0.010 |
| ≥4 | 0.647 (0.343–1.221) | 0.176 | 0.667 (0.353–1.261) | 0.212 |
|
| ||||
| <4 | 0.629 (0.426–0.929) | 0.019 | 0.631 (0.427–0.932) | 0.021 |
| ≥4 | 0.482 (0.217–1.073) | 0.068 | 0.482 (0.217–1.073) | 0.074 |
OR, odds ratio; CI, confidence interval; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; aadjusted for sex and age.
Figure 1Linkage disequilibrium (LD) analysis of the (a) TNFAIP3 and (b) TNIP1 SNPs. The LD status is expounded by the D′ value. D′ > 0.9 but r2 < 0.4 in all the blocks.
Results of TNFAIP3 and TNIP1 haplotype frequencies.
| Combinations of markers | Haplotypes | AS | HC | OR (95% CI) |
|
|---|---|---|---|---|---|
|
| |||||
| rs13207033-rs10499194 | Ht1 (GC) | 0.899 | 0.878 | 1.228 (0.964–1.564) | 0.096 |
| Ht2 (AC) | 0.064 | 0.062 | 1.026 (0.750–1.402) | 0.877 | |
| Ht3 (AT) | 0.036 | 0.058 | 0.601 (0.416–0.868) | 0.006 | |
| rs2230926-rs610604 | Ht4 (TT) | 0.876 | 0.867 | 1.076 (0.858–1.350) | 0.525 |
| Ht5 (TG) | 0.090 | 0.091 | 0.982 (0.754–1.279) | 0.893 | |
| Ht6 (GT) | 0.034 | 0.041 | 0.831 (0.557–1.238) | 0.361 | |
|
| |||||
| rs4958881-rs3792783-rs6889239 | Ht7 (TAC) | 0.528 | 0.524 | 1.015 (0.872–1.182) | 0.847 |
| Ht8 (TAT) | 0.244 | 0.248 | 0.980 (0.822–1.169) | 0.823 | |
| Ht9 (TGC) | 0.146 | 0.141 | 1.044 (0.840–1.296) | 0.698 | |
| Ht10 (CGC) | 0.081 | 0.085 | 0.952 (0.723–1.254) | 0.725 | |
AS, ankylosing spondylitis; HC, healthy controls; OR, odds ratio; CI, confidence interval; TNFAIP3, tumor necrosis factor-α induced protein 3; TNIP1, TNFAIP3-interacting protein 1.
Comprehensive annotation of SNPs in strong LD (r2 > 0.8) with rs10499194.
| CHR | BP | SNP |
| A1 | A2 | Gene | Position | H3K4ME3a | H3K4ME1a | H3K27ACa | Regulome DBb | Weighted _PINESc |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6 | 138002061 | rs77027760 | 0.86 | A | G | TNFAIP3 | intergenic | T | T | T | 3a | 0.030 |
| 6 | 138002637 | rs10499194 | 1 | T | C | TNFAIP3 | intergenic | T | T | T | 4 | 0.184 |
| 6 | 138004508 | rs142761146 | 0.86 | A | T | TNFAIP3 | intergenic | 5 | 0.851 | |||
| 6 | 138004568 | rs80351603 | 1 | A | G | TNFAIP3 | intergenic | 6 | 0.851 | |||
| 6 | 138005428 | rs13205649 | 1 | G | C | TNFAIP3 | intergenic | 6 | 0.503 | |||
| 6 | 138008679 | rs66499821 | 1 | C | T | TNFAIP3 | intergenic | T | 6 | 0.564 | ||
| 6 | 138009900 | rs34654849 | 0.91 | T | C | TNFAIP3 | intergenic | T | T | No Data | 0.364 | |
| 6 | 138011151 | rs12525643 | 1 | G | A | TNFAIP3 | intergenic | No Data | 0.150 |
BP: base position; A1: effective allele; A2: reference allele; T: True, own the specific histone modification.
ahistone modifications were derived from Primary mononuclear and T cells from peripheral blood (Roadmap Epigenomics Consortium, http://www.roadmapepigenomics.org/);
bRegulome DB (http://www.regulomedb.org/) annotated SNPs with known and predicted regulatory elements in the intergenic region. The scores refer to the possible regulatory function of a SNP, 3a:TF binding, any motif and DNase peak; 4:TF binding and DNase peak; 5:TF binding or DNase; 6:other function;
cPINES (http://genetics.bwh.harvard.edu/pines) provided a powerful in silico method to prioritize and fine map functional noncoding variants. SNPs with lower P values indicated more abundant function.